Significance of metallothionein overexpression in human tumours

Histopathology

Volumn 31, Issue 3, 1997, Pages 211-214

  Jasani, B ^a   Schmid, K W ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOPROTEIN; METALLOTHIONEIN;

CARCINOGENESIS; CELL TYPE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; REVIEW; TUMOR GROWTH;

EID: 0030983989     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1997.2140848.x     Document Type: Review

References (52)

1. Kagi JHR. Overview of metallothionein. Metallobiochemistry Part B: metallothionein and related molecules. Methods Enzymol. 1993; 205; 613-626.
2. Soumillion A, Van Damme J, De Ley M. Cloning and specific polymerised-chain-reaction amplification of a third charge-separable human metallothionein isoform. Eur. J. Biochem. 1992; 209; 999-1004.
3. Masters BA, Quaife CJ, Erickson JC et al. Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J. Neurol. Sci. 1994; 14; 5844-5857.
4. Quaife CJ, Findley SD, Erickson JC et al. Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified epithelia. Biochemistry 1994; 33; 7250-7259.
5. Masters BA, Kelly EJ, Quaife CJ, Brinster RL, Palmitter RD. Targeted disruption of metallothionein I and II genes increases sensitivity to cadmium. Proc. Natl. Acad. Sci. USA 1994; 91; 584-588.
6. Liu Yp, Liu J, Iszard MB, Andrews GK, Palmiter RD, Klaassen C. Transgenic mice that overexpress metallothionein-1 are protected from cadmium lethality and hepatotoxicity. Toxicol. Appl. Pharmacol. 1995; 135; 222-228.
7. Coogan TP, Shiraishi N, Waalkes MP. Apparent quiescence of metallothionein gene in rat ventral prostate - association with cadmium-induced prostate tumours in rats. Environ. Health Perspec. 1994; 102(Suppl. 3); 137-139.
8. Waalkes MP, Diwan BA, Weghorst CM, Bare RM, Ward JM, Rice JM. Anticarcinogenic effects of cadmium in B6C3F1 mouse liver and lung. Toxicol. Appl. Pharmacol. 1991; 110; 327-335.
9. Goncharova EI, Rossman TG. A role for metallothionein in spontaneous mutagenesis. Cancer Res. 1994; 54; 5318-5323.
10. Kondo Y, Woo ES, Michaska AE, Choo KHA, Lazo JS. Metallothionein null-cells have increased sensitivity to anticancer drugs. Cancer Res. 1995; 55; 2021-2023.
11. Kelly SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241; 1813-1815.
12. Schmid KW, Ellis IO, Darke BM et al. Presence and possible significance of immunocytochemically demonstrable metallothionein overexpression in primary invasive ductal carcinoma of the breast. Virchows Archiv. A. 1993; 422; 153-159.
13. Fresno M, Wu W, Rodriguez JM, Nadji M. Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Archiv. A. Pathol. Anat. 1993; 423; 215-219.
14. Nadji M, Fresno M, Herrera A, Morales A. Metallothionein is predictor of tumour aggressiveness in node negative breast cancer. Lab. Invest. 1994; 70; A19.
15. Haerslev T, Jacobsen K, Nedergaard L, Zedeler K. Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases. Path. Res. Pract. 1994; 190; 675-681.
16. Goulding H, Jasani B, Pereira H et al. Metallothionein expression in human breast cancer. Br. J. Cancer 1995; 72; 968-972.
17. Haerslev T, Jacobsen K, Zedeler K. The prognostic significance of immunocytochemically detectable metallothionein in primary breast carcinomas. Acta Path. Microbiol. Immunol. Scand. 1995; 103; 279-285.
18. Bier B, Douglas-Jones AG, Totsch M et al. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant lesions. Breast Cancer Res. Treat. 1994; 30; 213-221.
19. Douglas-Jones AG, Schmid KW, Bier B et al. Metallothionein expression in duct carcinoma in situ of the breast. Hum. Pathol. 1995; 26; 217-222.
20. Zelger B, Sidoroff A, Hopll R, Ofner D, Jasani B, Schmid KW. Metallothionein expression in nonmelanoma skin cancer. Appl. Immunohistochem. 1994; 2; 254-260.
21. Zelger B, Hittmair A, Schir M et al. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 1993; 23; 257-264.
22. Elmes ME, Shukla B, Zelger B et al. Metallothionein immunoreactivity as a prognostic marker in human malignant melanoma. In: Anke M, Meissner D, Mills CF eds. Trace Elements in Man and Animals. Vol. 8. New York, London: Plenum Press, 1993; 759-762.
23. Lim K, Evans A, Adams M, Fish R, Dhundee J, Dallimore N, Jasani B. Association of immunohistochemically detectable metallothionein (IDMT) expression with malignant transformation in cervical neoplasia. J. Pathol. 1996; 178(Suppl.); 48A.
24. Sauerbrey A, Zintl F, Volm M. Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukaemia. Ann. Haematol. 1994; 69; 111-115.
25. Ohshio G, Imamura T, Okada N et al. Immunohistochemical study of metallothionein in pancreatic carcinomas. J. Cancer Res. Clin. Oncol. 1996; 122; 351-355.
26. Mulder TP, Verspaget HW, Janssens AR, De-Bruin PA, Griffioen G, Lamers CB. Neoplasia-related changes of two copper (Cu)/zinc (Zn) proteins in the human colons. Free Radic. Biol. Med. 1990; 9; 501-506.
27. Ofner D, Maier H, Riedmann B et al. Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival. Virchows Archiv. A. 1994; 425; 491-497.
28. Giuffre G, Barresi G, Sturniolo GC, Sarnelli R, Inca RD, Tuccari G. Immunohistochemical expression of metallothionein in normal human colorectal mucosa, in adenomas, and in adenocarcinomas and their associated metastases. Histopathology 1996; 29; 347-354.
29. Bahnson R, Banner BF, Ernstoff MS et al. Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. J. Urology 1991; 146; 1518-1520.
30. Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams RD. Absence of immunohistochemical metallothionein staining in bladder-tumour specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J. Urol. 1994; 152; 2272-2275.
31. Zelger BWH, Sidoroff A, Stanzl U et al. Deep penetrating dermatofibroma vs. dermatofibrosarcoma protruberans - a clinicopathologic comparison. Am. J. Surg. Pathol. 1994; 18; 677-686.
32. Nartey N, Cherian MG, Banerjee D. Immunohistochemical localization of metallothionein in human thyroid tumours. Am. J. Pathol. 1987; 129; 177-182.
33. Schmid KW, Greeff M, Hittmair A et al. Metallothionein expression in normal, hyperplastic, and neoplastic thyroid follicular and parafollicular C cells using monoclonal antimetallothionein antibody E9. Endocr. Pathol. 1994; 5; 114-122.
34. Bauknecht T, Angel P, Kohler M et al. Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor-alpha, myc, jun, and metallothionein in human ovarian carcinomas. Cancer 1993; 71; 419-429.
35. Kontozoglou TE, Banerjee D, Cherian MG. Immunohistochemical localization of metallothionein in human testicular embryonal carcinoma cells. Virchows Archiv. A. Pathol. Anat. 1989; 415; 545-549.
36. Hart BA, Voss GW, Vacek PM. Metallothionein in human lung carcinoma. Cancer Letters 1993; 75; 121-128.
37. Jasani B, Edwards M, Vujanic G et al. Infrequent overexpression of metallothionein (MT) in paediatric tumours and its possible significance. J. Pathol. 1997; 181; 38A.
38. Cherian MG, Huang PC, Klaassen CD, Liu Y-P, Longfellow DG, Waalkes MP. National Cancer Institute Workshop on possible roles of metallothionein in carcinogenesis. Cancer Res. 1993; 53; 922-925.
39. Cherian MG, Howell SB, Imura N et al. Contemporary isuues in toxicology - role of metallothionein in carcinogenesis. Toxicol. Appl. Pharmacol. 1994; 126; 1-5.
40. Ebadi M, Iversen PL. Metallothionein in carcinogenesis and cancer chemotherapy (review). Gen. Pharmcol. 1994; 25; 1297-1310.
41. Jasani B, Elmes ME. Immunohistochemical detection of metallothionein. Metallobiochemistry Part B: Metallothionein and related molecules. Methods Enzymol. 1993; 205; 95-107.
42. Jahroudi N, Foster R, Price-Haughey, Gedamu L. Cell-type specific and differential regulation of the human metallothionein genes. J. Biol. Chem. 1990; 265; 6506-6511.
43. Schmidt CJ, Hamer DH. Cell specificity and an effect of ras on human metallothionein gene expression. Proc. Natl. Acad. Sci. USA 1986; 83; 3346-3350.
44. Pattanaik A, Shaw III CF, Petering DH, Garvey J, Kraker AJ. Basal metallothionein in tumours: widespread presence of apoprotein. J. Inorg. Biochem. 1994; 54; 91-105.
45. Jasani B, Campbell F, Navahi H, Schmid KW, Williams GT. Clonal overexprcssion of metallothionein in normal colonic mucosa induced by somatic mutation. J. Pathol. 1996; 178(Suppl.); 37A.
46. Zeng J, Vallee BL, Kagi JHR. Zinc transfer from transcription factor IIIA fingers to thionein clusters. Proc. Natl. Acad. Sci. USA 1991; 88; 9984-9988.
47. Zeng J, Heuchel R, Schaffner W, Kagi JHR. Thionein (apothionein) can modulate DNA binding and transcription activation by zinc finger containing factor SP1. FEBS Lett. 1991; 279; 310-312.
48. Hainaut P, Milner J. A structural role for metal ions in the 'wild type' conformation of the tumour suppressor protein p53. Cancer Res. 1993; 53; 1739-1742.
49. Hainaut P, Verhaegh, Barnes D et al. Inactivation of p53 by chelation of intracellular zinc and preferential overexpression of metallothionein in breast tumours with no p53 mutations. Proceedings of 8th International p53 Workshop, Dundee, Scotland, 5-9 July 1996.
50. Oren M, Prives C. p53: upstream, downstream and off stream - a review of the 8th p 53 workshop (Dundee, July 5-9 1996). Biochim. Biophys. Acta (Reviews on Cancer) 1996; 1288; R13-R19.
51. Mageed A, Agrawal KC. Anti-sense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Therapy 1996; 3(Suppl.); 93.
52. Beattie JH, Richards MP. Analysis of metallothionein isoforms by capillary electrophoresis: optimisation of protein separation conditions using micellar electro-kinetic capillary chromatography. J. Chromatog. 1995; 700; 95-103.